WO1996015117A1 - Compose optiquement actif - Google Patents
Compose optiquement actif Download PDFInfo
- Publication number
- WO1996015117A1 WO1996015117A1 PCT/JP1995/002295 JP9502295W WO9615117A1 WO 1996015117 A1 WO1996015117 A1 WO 1996015117A1 JP 9502295 W JP9502295 W JP 9502295W WO 9615117 A1 WO9615117 A1 WO 9615117A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxo
- amino
- phenyl
- methyl
- cyclohexenyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/04—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having less than three double bonds between ring members or between ring members and non-ring members
Definitions
- the present invention relates to an optically active pyridazinone derivative useful as a platelet aggregation inhibitor and a method for producing the same.
- An object of the present invention is to provide an optically active pyridazinone derivative having a platelet aggregation inhibitory effect with less side effects and high stability.
- the present invention provides a compound represented by the formula (I):
- the amorphous racemate [(Earth) one (I)] of the compound of the present invention can be obtained, for example, by the production method described in WO949784.
- the crystallographic optically active compound of the present invention ((R)-(1-) 1-4.5-dihydro-5-methyl-6- [4-1-[(2-propyl-13-oxo-11-cyclohexenyl) amino] [Phenyl] -13 (2H) -pyridazinone) is obtained by converting this racemic form [( ⁇ )-[1]] into an optical isomer by, for example, optical resolution using a column chromatographic column.
- a solvent selected from the group consisting of water, a hydrophilic organic solvent such as ethanol, and a mixed solvent thereof the temperature is preferably from 120 to 80, preferably from 0 to 4 ° C. It can be produced by stirring, collecting the precipitated crystals, and drying them by a conventional method. At this time, crystallization can be promoted by coexisting the crystal as a seed.
- the mixed solvent of water and organic solvent may contain 5% to 95% water, and preferably 30 to 70% water-containing organic solvent.
- a crystal may be obtained by the operation of a column chromatographic column for separating optical isomers, but such a crystal is, of course, included in the crystal of the present invention.
- a column for enantiomer separation preferably, CHIRALCEL0D, 0J. CHIRA L PAK AD, AS (Daicel Chemical). SUM I CH I RAL
- the reaction is carried out in an inert organic solvent, preferably a solvent such as benzene, toluene, xylene, low-alcohol, DMF, DMS 0, etc., and preferably an acid such as a carrier acid, sulfuric acid, drunk acid, or P-toluenesulfonic acid. It is carried out by heating to room temperature to 200 in the presence of a catalyst. At this time, the removal can be performed more effectively by removing generated water by means such as azeotropic dehydration.
- the products are ethyl acetate, black form, methanol, Optical purity can be increased by recrystallization from a mixed solvent of ethanol, ethanol and water.
- a mixed solvent of benzene or toluene and DMS O or DMF is used as a reaction solvent, and p-toluenesulfonic acid is used as an acid catalyst in an amount of 0.1 to 0.001 mol per 1 mol of the amino compound.
- the desired product can be obtained with high optical purity (95% or more).
- (R) 16- (aminophenyl) -15-methylbiridazine-13 (2H) one [ ⁇ ] is produced by a known method.
- it can be produced from a racemate by performing optical resolution according to the method described in WO 9221135 or the like, or can be produced from an optically active acid chloride as shown in the following reaction formula.
- [II] (R) of the present invention (I) -I4.5-Dihydro-5-methyl-6- [4-1 ((2-Ipropyl-13-oxo-11-cyclohexenyl) amino] phenyl] 1 3 (2H) -Pyridazinone or a pharmaceutically acceptable complex can be administered to humans and animals as it is or together with a pharmaceutical carrier for resentment.
- dosage unit forms include, for example, oral preparations such as tablets, granules and oral solutions, and parenteral preparations such as injections.
- the amounts of the components, and the dosage form and selection It can be appropriately selected from a wide range depending on the individual compound and the human or animal to be administered.
- oral preparations such as tablets, capsules, and oral solutions are produced according to a conventional method. That is, tablets are prepared by mixing the compound of the present invention or a pharmaceutically acceptable complex and mixing with pharmaceutical excipients such as starch, lactose, gelatin, magnesium stearate, talc, arabia gum and the like. .
- Capsules are produced by mixing the compound of the present invention or a pharmaceutically acceptable complex with an inert pharmaceutical filler or diluent, and filling the mixture with hard gelatin capsules, K capsules, or the like. You.
- a syrup or elixir is prepared by mixing a sweetening agent such as sucrose, a preservative such as methyl- and probi-parabens, a coloring agent and a seasoning.
- a sweetening agent such as sucrose
- a preservative such as methyl- and probi-parabens
- a coloring agent such as methyl- and probi-parabens
- Parenteral preparations are manufactured according to the usual methods. That is, a drug for parenteral administration is produced by dissolving the compound of the present invention or a pharmaceutically acceptable complex in a sterilized liquid carrier.
- Preferred carriers are water or saline. Liquids with the desired clarity, stability and adaptability for parenteral use are about 1 to
- Such a liquid preparation preferably contains a lubricant such as polyvinylpyrrolidone, polyvinyl alcohol, sodium carboxymethyl cellulose and methyl cellulose.
- bactericides such as benzyl alcohol, phenol, and thimerosal, as well as antibacterial agents, and, if necessary, isotonic agents such as sucrose and sodium chloride, local anesthetics, stabilizers, and buffering agents. May be included.
- the drug for parenteral administration is frozen after filling, and water can be removed by a freeze-drying technique known in the art.
- the lyophilized powder can be re-prepared immediately before use.
- FIG. 1 shows the crystallinity (R) of the present invention (1) —4,5-dihidro 5-methyl
- FIG. 4 is an X-ray powder diffraction pattern of 6- [4-1 [(2-propyl-13-oxo-1-cyclohexenyl) amino] phenyl] -13 (2H) -pyridazinone.
- Tube voltage 40kV
- tube current 20mA
- Fig. 1 shows the powder X-ray diffraction pattern of this product for reference. Next, test examples of the pharmacological action of the compound of the present invention will be described.
- the platelet aggregation inhibitory effect was measured using a hematizer tracer PAT-606 from Nikko Biosciences Co., Ltd. using an aggregometer, adenosine diphosphate (ADP), collagen, arachidonic acid, U- In vitro activity was evaluated for inhibition of platelet aggregation induced by 4661 and thrombin. Blood with 0.38% citrate added from rabbits was rapidly centrifuged at 1200 rpm for 15 minutes to obtain plasma [p1 at 1 etrichplasma (PRP)] having a high platelet concentration.
- ADP adenosine diphosphate
- PRP platelet concentration
- the test compound was dissolved in dimethylsulfoxide (DMS 0), 0.2 ml of the PRP sample prepared above was added to 0.21, and the mixture was pre-incubated for 3 minutes.
- the platelet aggregation inhibitory effect was calculated as the inhibition rate (%) with respect to the maximum aggregation rate of the control.
- the aggregation inhibition rate was calculated according to the following equation.
- the (R) form of the formula (I) showed about 300 to 400 times the use for production of platelet aggregation suppression compared to the (S) form.
- Example 2 When the crystalline compound of the present invention obtained in Example 2 was tested under the same conditions, it showed an excellent inhibitory effect on platelet aggregation similar to that of the non-S form (R)-(I) -I (I).
- the amorphous powder obtained as described above and the crystal obtained in Example 2 were each 10018, sealed in a 20 ml vial, and stored at 80 ° C for 4 days. After returning to room temperature, the residual ratio (%) of the test drug was measured by high performance liquid chromatography (HPLC).
- the residual solvent was analyzed using the same amorphous powder and crystals used in Test Example 2.
- the compound of the present invention has few side effects and has an excellent platelet aggregation inhibitory effect, and is therefore useful as an antithrombotic agent. Furthermore, the compounds of the present invention have a bronchodilator effect and are therefore useful in the treatment of chronic obstructive pulmonary diseases such as asthma and bronchitis.
- the compounds of the present invention are useful for treating various diseases related to the concentration of intracellular cAMP (such as hypertension, Ban, diabetes, and cancer).
- Crystals are also ideal for providing stable and uniform bulk.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/817,872 US5856480A (en) | 1994-11-11 | 1995-11-10 | Optically active compound |
AU38559/95A AU3855995A (en) | 1994-11-11 | 1995-11-10 | Optically active compound |
EP95936766A EP0791584A4 (en) | 1994-11-11 | 1995-11-10 | OPTICALLY ACTIVE CONNECTIONS |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6/301674 | 1994-11-11 | ||
JP30167494 | 1994-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996015117A1 true WO1996015117A1 (fr) | 1996-05-23 |
Family
ID=17899770
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1995/002295 WO1996015117A1 (fr) | 1994-11-11 | 1995-11-10 | Compose optiquement actif |
Country Status (6)
Country | Link |
---|---|
US (1) | US5856480A (ja) |
EP (1) | EP0791584A4 (ja) |
AU (1) | AU3855995A (ja) |
CA (1) | CA2204915A1 (ja) |
TW (1) | TW319765B (ja) |
WO (1) | WO1996015117A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7601720B2 (en) * | 2001-03-23 | 2009-10-13 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
US8039459B2 (en) | 2004-07-15 | 2011-10-18 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
US8557804B2 (en) | 2002-03-25 | 2013-10-15 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
CN114601837A (zh) * | 2016-02-05 | 2022-06-10 | 拜耳医药股份公司 | 用于癌症患者分级和癌症治疗的化合物、组合物和方法 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR0308525A (pt) * | 2002-03-22 | 2005-02-01 | Lg Life Sciences Ltd | Formas cristalinas |
JP6511430B2 (ja) | 2013-03-11 | 2019-05-15 | ザ・ブロード・インスティテュート・インコーポレイテッド | がんの治療のための化合物および組成物 |
WO2017027854A1 (en) | 2015-08-13 | 2017-02-16 | The Broad Institute, Inc. | Compositions and methods for cancer expressing pde3a or slfn12 |
CN110117257B (zh) * | 2018-02-05 | 2022-12-06 | 安徽省新星药物开发有限责任公司 | 一种含胍基的p2y12受体拮抗剂、制备方法及其用途 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61212583A (ja) * | 1985-03-12 | 1986-09-20 | スミス・クライン・アンド・フレンチ・ラボラトリース・リミテツド | 2‐アミノピリミジノン誘導体 |
JPH05140116A (ja) * | 1991-11-21 | 1993-06-08 | Nippon Soda Co Ltd | 光学活性な化合物 |
JPH06192098A (ja) * | 1992-11-02 | 1994-07-12 | Nippon Soda Co Ltd | 血小板凝集抑制剤 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2717687B2 (ja) * | 1988-02-13 | 1998-02-18 | 日本曹達株式会社 | ピリダジノン誘導体及びその製造方法 |
GB2251615B (en) * | 1991-01-03 | 1995-02-08 | Orion Yhtymae Oy | (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile |
-
1995
- 1995-11-10 WO PCT/JP1995/002295 patent/WO1996015117A1/ja not_active Application Discontinuation
- 1995-11-10 EP EP95936766A patent/EP0791584A4/en not_active Withdrawn
- 1995-11-10 AU AU38559/95A patent/AU3855995A/en not_active Abandoned
- 1995-11-10 CA CA002204915A patent/CA2204915A1/en not_active Abandoned
- 1995-11-10 US US08/817,872 patent/US5856480A/en not_active Expired - Fee Related
-
1996
- 1996-01-15 TW TW085100414A patent/TW319765B/zh active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61212583A (ja) * | 1985-03-12 | 1986-09-20 | スミス・クライン・アンド・フレンチ・ラボラトリース・リミテツド | 2‐アミノピリミジノン誘導体 |
JPH05140116A (ja) * | 1991-11-21 | 1993-06-08 | Nippon Soda Co Ltd | 光学活性な化合物 |
JPH06192098A (ja) * | 1992-11-02 | 1994-07-12 | Nippon Soda Co Ltd | 血小板凝集抑制剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0791584A4 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7601720B2 (en) * | 2001-03-23 | 2009-10-13 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
US8377936B2 (en) | 2001-03-23 | 2013-02-19 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
US8551983B2 (en) | 2002-03-25 | 2013-10-08 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
US8557804B2 (en) | 2002-03-25 | 2013-10-15 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
US8039459B2 (en) | 2004-07-15 | 2011-10-18 | Universite Laval | Nicotinic receptor agonists for the treatment of inflammatory diseases |
EP2218442A1 (en) | 2005-11-09 | 2010-08-18 | CombinatoRx, Inc. | Methods, compositions, and kits for the treatment of ophthalmic disorders |
WO2013106547A1 (en) | 2012-01-10 | 2013-07-18 | President And Fellows Of Harvard College | Beta-cell replication promoting compounds and methods of their use |
CN114601837A (zh) * | 2016-02-05 | 2022-06-10 | 拜耳医药股份公司 | 用于癌症患者分级和癌症治疗的化合物、组合物和方法 |
Also Published As
Publication number | Publication date |
---|---|
EP0791584A1 (en) | 1997-08-27 |
EP0791584A4 (en) | 1997-11-19 |
AU3855995A (en) | 1996-06-06 |
TW319765B (ja) | 1997-11-11 |
CA2204915A1 (en) | 1996-05-23 |
US5856480A (en) | 1999-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2408595C2 (ru) | Сокристаллическая форма производного с-гликозида c l-пролином | |
EP1814856A1 (en) | Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes | |
JP2000204070A (ja) | 新規なアリールエテニレン誘導体及びその製法 | |
US5041443A (en) | Medicament for treating cerebral insufficiency diseases, novel 2-(1-piperazinyl)-4-phenylcycloalkanopyrimidine derivatives, and process for the production thereof | |
EP0281459A1 (fr) | Enantiomère dextrogyre de l'alpha-(tétrahydro-4,5,6,7 thiéno (3,2-c)pyridyl-5) (chloro-2 phényl)-acétate de méthyle, son procédé de préparation et les compositions pharmaceutiques le renfermant | |
WO1996015117A1 (fr) | Compose optiquement actif | |
CN111039937B (zh) | 一种利伐沙班中间体的制备方法 | |
JP2000063340A (ja) | 抗腫瘍活性を有するフェノキシ酢酸及びフェノキシメチルテトラゾ―ルの誘導体 | |
KR100479897B1 (ko) | 다형태 염 | |
CN116874469B (zh) | 一种氧代吡啶类化合物、中间体及其制备方法和用途 | |
FR2527608A1 (fr) | Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments | |
JP4181219B2 (ja) | 環縮合したジヒドロピラン類、その製造方法およびその使用 | |
TW201936580A (zh) | 一種酮基吡啶醯胺類衍生物的晶型及其製備方法 | |
JPS62270564A (ja) | ピラジン誘導体およびこれを含有する血小板凝集抑制剤 | |
FR2687146A1 (fr) | Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. | |
JPH07291974A (ja) | エピ−エピバチジン誘導体及びその製造法 | |
JP2008514711A (ja) | ピラゾロ[3,4−c]ピリジンXA因子阻害剤の結晶フォーム | |
KR20140022851A (ko) | 오타믹사반의 벤조산염 | |
JPH0575728B2 (ja) | ||
HUT75114A (en) | 1-oxo-2-(phenylsulfonyl-amino)-pentylpiperidine derivatives, process for producing them and pharmaceutical use of them | |
US20060094764A1 (en) | Cyanothiophenes, their preparation and their use in pharmaceutical compositions | |
WO2005054229A1 (fr) | Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique | |
CN116947818B (zh) | 一种氧代吡啶类化合物、中间体及其制备方法和用途 | |
CN112004810B (zh) | 一种氧代吡啶酰胺类衍生物的晶型及制备方法 | |
MXPA04010846A (es) | Proceso para preparar 1, 2, 3, 9-tetrahidro -9- metil-3 -[(2-metil -1h-imidazol -1-il) metil]- 4h- carbazol -4- ona. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KE KG KR KZ LK LT LU LV MD MG MN MW NO NZ PL PT RO RU SD SE SI SK TJ TT UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 08817872 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2204915 Country of ref document: CA Ref country code: CA Ref document number: 2204915 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995936766 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1995936766 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1995936766 Country of ref document: EP |